先天性心脏病手术后体外膜氧合早期结局
该研究纳入2001至2024年同一中心9892例先天性心脏病手术患者,178例(1.8%)需要围术期静脉-动脉体外膜氧合支持,中位支持6天。院内死亡率为55%,延长ECMO支持时间和需要肾脏替代治疗的急性肾衰竭与死亡独立相关,支持超过6天后预测死亡率急剧上升。
要点
- 先天性心脏病手术后约1.8%需要ECMO支持,总体存活率约50%。
- ECMO支持时间延长和需要肾脏替代治疗的急性肾衰竭是死亡的独立相关因素。
- ECMO支持超过6天后预测死亡率急剧上升,需早期重新评估可逆性。
核心结论
- 先天性心脏病手术后约2%的患者需要ECMO支持,总体存活率约50%。
- 延长的ECMO支持时间和需要肾脏替代治疗的急性肾衰竭与死亡独立相关。
- ECMO支持超过6天后死亡率急剧增加,提示需早期重新评估可逆性并考虑替代策略。
研究设计与样本
- 回顾性单中心研究,纳入2001年至2024年所有接受先天性心脏病手术的患者,共9892例手术。
- 分析ECMO支持的患病率、结局、ECMO支持的危险因素以及ECMO后院内死亡的预测因素。
主要发现
- 9892例先天性心脏病手术中,178例(1.8%)需要ECMO支持,中位支持时间6天(四分位距4-9)。
- 手术时中位年龄2.8个月(四分位距0.4-25.2),中位体重4.1 kg(四分位距3.2-8.9)。
- 在≤2岁患者中,Norwood手术和冠状动脉畸形手术是ECMO支持的独立危险因素。
- 成功脱离ECMO者占62%(n=111),17%(n=30)需要第二次ECMO运行。
- ECMO后院内死亡率为55%(n=98),发生于手术后中位16天(四分位距5-34);27%的患者在首次成功脱离后死亡。
临床怎么用
- 对于先天性心脏病手术后需要ECMO支持的患者,应密切监测ECMO支持时间和肾功能,及时处理急性肾衰竭。
- ECMO支持超过6天时需重新评估病情可逆性,并考虑替代策略如心室辅助装置或移植评估。
局限性
- 单中心回顾性研究,结果外推需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Extracorporeal membrane oxygenation is widely used to treat cardiopulmonary failure after congenital heart surgery. This study evaluated patient characteristics, outcomes, and risk factors associated with perioperative veno-arterial extracorporeal membrane oxygenation use. METHODS: All patients undergoing congenital heart surgery between 2001 and 2024 at our centre were included. Prevalence, outcomes, risk factors for extracorporeal membrane oxygenation support, and predictors of in-hospital mortality following extracorporeal membrane oxygenation were analysed. RESULTS: Among 9892 congenital heart operations, extracorporeal membrane oxygenation was required in 178 (1.8%) patients for a median of 6 days (interquartile range 4-9). Median age and weight at surgery were 2.8 months (interquartile range 0.4-25.2) and 4.1 kg (interquartile range 3.2-8.9), respectively. In patients ≤2 years, the Norwood procedure and surgery for coronary artery malformations were independent risk factors for extracorporeal membrane oxygenation support. Successful weaning was achieved in 62% (n = 111), while 17% (n = 30) required a second extracorporeal membrane oxygenation run. In-hospital mortality after extracorporeal membrane oxygenation was 55% (n = 98), occurring a median of 16 days (interquartile range 5-34) after surgery; 27% of the patients died after a successful first weaning. Model-based predictions showed an 8-fold increase between days 6 and 12 of extracorporeal membrane oxygenation support, with predicted mortality rising from 26% to 74%. CONCLUSIONS: Approximately 2% of patients undergoing congenital heart surgery require extracorporeal membrane oxygenation support with an overall survival rate of around 50%. Prolonged extracorporeal membrane oxygenation duration and acute renal failure requiring renal replacement therapy were independently associated with mortality. The sharp increase in mortality beyond 6 days of extracorporeal membrane oxygenation highlights the need for early reassessment of reversibility and timely consideration of alternative strategies.
引用
- Schaeffer T, Hayat S, Matsubara M, et al. Early Outcomes of Extracorporeal Membrane Oxygenation in Congenital Heart Surgery. Eur J Cardiothorac Surg. 2026. PMID: 41832988. doi:10.1093/ejcts/ezag123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。